Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
65.11
-0.66 (-1.00%)
At close: Dec 18, 2025, 4:00 PM EST
64.87
-0.24 (-0.37%)
After-hours: Dec 18, 2025, 5:28 PM EST
Halozyme Therapeutics Revenue
Halozyme Therapeutics had revenue of $354.26M in the quarter ending September 30, 2025, with 22.12% growth. This brings the company's revenue in the last twelve months to $1.24B, up 31.19% year-over-year. In the year 2024, Halozyme Therapeutics had annual revenue of $1.02B with 22.44% growth.
Revenue (ttm)
$1.24B
Revenue Growth
+31.19%
P/S Ratio
6.46
Revenue / Employee
$3,551,006
Employees
350
Market Cap
7.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.02B | 186.07M | 22.44% |
| Dec 31, 2023 | 829.25M | 169.14M | 25.62% |
| Dec 31, 2022 | 660.12M | 216.81M | 48.91% |
| Dec 31, 2021 | 443.31M | 175.72M | 65.67% |
| Dec 31, 2020 | 267.59M | 71.60M | 36.53% |
| Dec 31, 2019 | 195.99M | 44.13M | 29.06% |
| Dec 31, 2018 | 151.86M | -164.75M | -52.04% |
| Dec 31, 2017 | 316.61M | 169.92M | 115.84% |
| Dec 31, 2016 | 146.69M | 11.63M | 8.61% |
| Dec 31, 2015 | 135.06M | 59.72M | 79.28% |
| Dec 31, 2014 | 75.33M | 20.54M | 37.47% |
| Dec 31, 2013 | 54.80M | 12.47M | 29.47% |
| Dec 31, 2012 | 42.33M | -13.76M | -24.54% |
| Dec 31, 2011 | 56.09M | 42.46M | 311.67% |
| Dec 31, 2010 | 13.62M | -47.19K | -0.35% |
| Dec 31, 2009 | 13.67M | 4.91M | 55.99% |
| Dec 31, 2008 | 8.76M | 4.96M | 130.66% |
| Dec 31, 2007 | 3.80M | -977.95M | -99.61% |
| Dec 31, 2006 | 981.75M | 854.54M | 671.76% |
| Dec 31, 2005 | 127.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
HALO News
- 12 hours ago - U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer - PRNewsWire
- 3 days ago - Halozyme's Elektrofi Deal: Site-Of-Care Optionality (Rating Upgrade) - Seeking Alpha
- 10 days ago - Jim Lang Elected to Halozyme's Board of Directors - PRNewsWire
- 14 days ago - Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case - WSJ
- 14 days ago - Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany - PRNewsWire
- 16 days ago - Halozyme Therapeutics, Inc. (HALO) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 23 days ago - Halozyme to Participate in the 8th Annual Evercore Healthcare Conference - PRNewsWire
- 4 weeks ago - Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery - PRNewsWire